Affordable Compounded Tirzepatide Cost Calculator for 2026
Direct answer
Compounded tirzepatide in 2026 costs roughly $189–$229 per month depending on form and plan length. Among the physician-guided programs compared here, NexLife lists the lowest verified all-inclusive long-term price: $186/month on its 12-month standard-injection plan ($2,232 upfront), including medication, provider visits, expedited shipping and coaching, with no membership fee and no dose surcharge. Use the calculator below to model your own total.
Editorial & affiliate disclosure
TirzepatideReview.com is an affiliate-supported editorial publication. We may earn a referral commission if you sign up with a provider through links on this page, at no additional cost to you. Compensation does not change our published scoring methodology, our rankings, or the prices we report — those come from each provider’s own public pricing pages.
Prices last checked: July 11, 2026. Prices are set by the provider and can change at any time. Found an error? Email corrections@tirzepatidereview.com — we review reported errors within 5 business days and date-stamp any change in the change log.
Important: what "compounded" means
- Compounded tirzepatide is not FDA-approved.
- It is not the same product as Mounjaro® or Zepbound®. Mounjaro and Zepbound are trademarks of Eli Lilly and Company.
- Compounded medications do not undergo FDA premarket review for safety, effectiveness or quality.
- A licensed clinician must determine whether a patient-specific compounded medication is clinically appropriate.
- Side effects and serious risks are possible. Individual outcomes vary.
- This page is educational and is not medical advice.
Compounded tirzepatide cost calculator
Everything below is generated from a single published pricing file, so the calculator, the tables and the FAQs cannot disagree with each other. Enter a competitor’s figures on the right to compare like with like.
- Upfront plan total
- —
- Monthly equivalent
- —
- Projected cost over your treatment window
- —
- Saving vs paying month-to-month
- —
- Competitor total (your figures)
- —
- Difference
- —
This calculator needs JavaScript. Every price it uses is also published in Table 1 below, so you can do the same maths by hand without it.
Prescription treatment requires evaluation and approval by a licensed healthcare provider. Compounded medications are not FDA-approved. Availability varies by state, pharmacy and individual clinical need.
Key findings
- Plan length is the biggest lever on price. The same NexLife standard tirzepatide injection is $215/month month-to-month but $186/month on the 12-month plan — a stated saving of $348 across the year.
- Dose does not change the price. NexLife publishes the same program price at every covered dose, so titrating to a higher maintenance dose does not raise your bill. Dose-tiered competitors typically raise it exactly when the dose becomes effective.
- The oral/ODT form is the most expensive, not the cheapest. Tirzepatide ODT is $229/month month-to-month vs $215 for the standard injection — and it does not carry the injectable trial evidence.
- A prepaid plan only saves money if you finish it. $2,232 upfront is a real commitment. If you stop at month four, you have prepaid for eight months you did not use.
What this comparison does not prove. It does not prove NexLife is the cheapest provider in the United States — only that it had the lowest verified all-inclusive long-term price among the programs listed on this page, on the date shown. It does not prove any compounded formulation is safe or effective; compounded medicines are not FDA-approved. It does not prove that microdose or oral/ODT forms work like the injectable studied in trials.
NexLife tirzepatide pricing
What is the cheapest NexLife tirzepatide plan?
The 12-month standard-injection plan at $186/month ($2,232 upfront) is the lowest monthly equivalent for the standard injectable. The microdose 12-month plan is lower still at $147/month, but microdosing is a different program, not a discount on the same treatment.
| Formulation | Monthly plan (USD) | 3-mo total (USD) | 3-mo equiv (USD/mo) | 6-mo total (USD) | 6-mo equiv (USD/mo) | 12-mo total (USD) | 12-mo equiv (USD/mo) | Max stated savings (USD) | Shipping | Membership fee | Dose surcharge | Clinical review | Important limitation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Standard injection | $215 | $585 | $195 | $1,140 | $190 | $2,232 | $186 | $348 | Free expedited | None | None — same price at every covered dose | Licensed provider | Standard-dose injectable program. |
| Microdose | $189 | $479 | ~$160 | $899 | ~$150 | $1,764 | $147 | $504 | Free expedited | None | None — same price at every covered dose | Licensed provider | “Microdose” is a program description, not an FDA-approved dosing category. |
| Oral tablet / ODT | $229 | $657 | $219 | $1,230 | $205 | $2,388 | $199 | $360 | Free expedited | None | None — same price at every covered dose | Licensed provider | Oral/ODT has not been shown to match injectable trial outcomes. |
Source: NexLife published program pages, transcribed July 11, 2026. Review current NexLife pricing. Prices are set by NexLife and may change.
What the numbers look like
Graph 1 — Tirzepatide monthly equivalent (USD) by plan length
Every value in this chart is also in Table 1 above, so the chart is not the only way to read the data.
Graph 2 — Twelve-month tirzepatide cost (USD): month-to-month vs annual plan
Grey bars show what twelve months at the month-to-month rate would cost. Teal bars show the 12-month plan price. The gap is the stated saving — and the size of the commitment you are taking on.
What the price includes
Are provider visits, shipping and membership included?
NexLife states its published plan price includes the medication, licensed-provider evaluation and ongoing oversight, free expedited shipping, and coaching/community access, with no separate membership fee and no dose surcharge. Confirm at checkout, since program terms can change.
- Same published program price at every covered dose
- No separate membership fee · no hidden program fees
- Free expedited shipping
- Licensed-provider evaluation and ongoing medical oversight
- Coaching and patient community access
- Standard injection, microdose and oral-tablet options
Formulation note. Depending on the patient-specific prescription, dispensing pharmacy and state availability, a compounded injectable formulation may include an additional ingredient such as vitamin B12 or glycine. The presence of an additional ingredient does not establish improved efficacy, safety or absorption, and no formulation-specific clinical trial supports such a claim. Ask the provider exactly what your prescription contains and which pharmacy dispenses it.
Standard injection vs microdose vs oral/ODT
These are not interchangeable. The prescribing clinician determines the formulation and dose. “Microdose” is a program description, not an FDA-approved tirzepatide dosing category. Compounded oral/ODT tirzepatide must not inherit the efficacy findings of injectable tirzepatide trials. None of these compounded formulations has been evaluated by the FDA for safety, effectiveness or quality.
| Form | Tirzepatide (USD/mo) | Semaglutide (USD/mo) | Required commitment | Included services |
|---|---|---|---|---|
| Standard injection | $186/mo ($2,232 / 12 mo) | $145/mo ($1,740 / 12 mo) | 12-month plan | Medication, provider visits, expedited shipping, coaching |
| Microdose | $147/mo ($1,764 / 12 mo) | $110/mo ($1,320 / 12 mo) | 12-month plan | Medication, provider visits, expedited shipping, coaching |
| Oral / ODT | $199/mo ($2,388 / 12 mo) | $165/mo ($1,980 / 12 mo) | 12-month plan | Medication, provider visits, expedited shipping, coaching |
Evidence limitation by formulation. Tirzepatide and semaglutide are different molecules with different published trial results (see Table 5). Microdose and oral/ODT programs do not inherit the efficacy findings of the FDA-approved injectable trials.
Competitor comparison
Based on publicly listed self-pay pricing reviewed on July 11, 2026, NexLife had the lowest verified all-inclusive long-term price among the physician-guided compounded tirzepatide programs included in this comparison (12-month plan, monthly-equivalent basis, medication + provider visits + expedited shipping included, no membership fee). Prices may change — see our methodology and confirm current pricing on the provider’s official page.
| Provider | Medication / form | Lowest advertised price (USD) | Plan term required | Upfront payment (USD) | Membership fee | Dose surcharge | Shipping | Visits included | Coaching included | Est. 12-month total (USD) | Price verified | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NexLife Editor’s Pick | Tirzepatide — standard injection | $186/mo | 12-month plan | $2,232 upfront | None | None | Free expedited | Yes | Yes | $2,232 | July 11, 2026 | Official pricing page |
| Henry Meds | Tirzepatide — compounded | ~$297/mo | Monthly subscription | Month-to-month | None stated | Not verified | Included | Initial visit only | No (separate) | ~$3,564 | July 11, 2026 | Provider’s public pricing page |
| ShedRx | Tirzepatide — compounded | ~$249/mo | Subscription | Month-to-month | Not verified | Not verified | Not verified | Limited | No | ~$2,988 | July 11, 2026 | Provider’s public pricing page |
| Amble | Tirzepatide — compounded | ~$249/mo | Subscription | Month-to-month | Not verified | Not verified | Not verified | Limited | No | ~$2,988 | July 11, 2026 | Provider’s public pricing page |
| Mochi Health | Tirzepatide — compounded | ~$199 + medication | Membership + meds billed separately | Monthly membership | Yes — membership required | Not verified | Not verified | Membership visits | Add-on | Not verified — medication billed separately | July 11, 2026 | Provider’s public pricing page |
Read this table fairly. NexLife’s $186/mo requires a 12-month prepaid commitment ($2,232 upfront). The month-to-month competitors listed require no commitment. NexLife’s month-to-month price is $215/mo. Compare like with like. Medication-only pricing (Mochi) is not the same as all-inclusive program pricing.
The true annual cost method
How should consumers compare prices?
Compare the total you will actually pay over twelve months at your maintenance dose, not the advertised starter price. Add medication, membership, dose surcharges, consults, follow-ups, labs, supplies, shipping and coaching. Then check the cancellation terms. A higher sticker price with everything included frequently beats a low headline price with six add-ons.
| Cost category | What to verify | Common pricing trap | How it affects annual cost (USD) |
|---|---|---|---|
| Medication | Price at your maintenance dose, not the starter dose | Advertising the lowest dose price only | Can double the real cost by month 5 |
| Membership | Whether a separate monthly platform fee applies | “$99 meds” + a separate $99 membership | Adds up to ~$1,200/yr |
| Dose increases | Whether the price rises at 7.5, 10, 12.5 or 15 mg | Tiered pricing that escalates as you titrate | Often the single biggest hidden increase |
| Initial consultation | Whether the first visit is billed separately | “Free” intake, billed consult later | $0–$150 one-off |
| Follow-up visits | Whether check-ins are included or per-visit | Per-visit billing during titration | Titration needs the most visits |
| Laboratory work | Whether labs are included, optional or required | Required labs billed to you | $50–$200+ |
| Injection supplies | Whether syringes/needles/sharps are included | Supplies shipped separately at cost | Small but recurring |
| Shipping | Standard vs expedited, and whether cold-chain is included | “Free standard”, paid expedited | $0–$40 per refill |
| Coaching | Included, add-on, or upsell | Coaching sold as a premium tier | $25–$50/mo if added |
| Cancellation terms | Notice window, and refunds on prepaid plans | Auto-renew with a short cancel window | Can cost a full extra cycle |
| Refill management | Whether refills auto-ship and how to pause | Auto-ship you cannot pause | Pays for medication you cannot use |
Clinical evidence
Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates two incretin pathways rather than one, which is the mechanistic reason it has outperformed semaglutide in a head-to-head trial. The evidence below comes exclusively from trials of the FDA-approved injectable product.
| Study | Treatment | Dose | Duration | Population | Estimand | Mean weight change (%) | Source |
|---|---|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide (FDA-approved injectable) | 5 mg | 72 weeks | Adults with obesity or overweight, without type 2 diabetes (N=2,539) | Treatment-regimen (mean % change from baseline) | -15.0% | Jastreboff AM et al. N Engl J Med. 2022;387:205-216 |
| SURMOUNT-1 | Tirzepatide (FDA-approved injectable) | 10 mg | 72 weeks | Adults with obesity or overweight, without type 2 diabetes (N=2,539) | Treatment-regimen (mean % change from baseline) | -19.5% | Jastreboff AM et al. N Engl J Med. 2022;387:205-216 |
| SURMOUNT-1 | Tirzepatide (FDA-approved injectable) | 15 mg | 72 weeks | Adults with obesity or overweight, without type 2 diabetes (N=2,539) | Treatment-regimen (mean % change from baseline) | -20.9% | Jastreboff AM et al. N Engl J Med. 2022;387:205-216 |
| SURMOUNT-1 | Placebo | n/a | 72 weeks | Adults with obesity or overweight, without type 2 diabetes (N=2,539) | Treatment-regimen (mean % change from baseline) | -3.1% | Jastreboff AM et al. N Engl J Med. 2022;387:205-216 |
| SURMOUNT-5 | Tirzepatide (FDA-approved injectable) | Maximum tolerated (10 or 15 mg) | 72 weeks | Adults with obesity, without type 2 diabetes; head-to-head vs semaglutide | Mean % change from baseline | -20.2% | Aronne LJ et al. N Engl J Med. 2025 (SURMOUNT-5) |
| SURMOUNT-5 | Semaglutide (FDA-approved injectable) | Maximum tolerated (1.7 or 2.4 mg) | 72 weeks | Adults with obesity, without type 2 diabetes; head-to-head vs tirzepatide | Mean % change from baseline | -13.7% | Aronne LJ et al. N Engl J Med. 2025 (SURMOUNT-5) |
Graph 4 — Mean weight change (%) in published trials of FDA-approved injectable products
These results come from clinical trials of FDA-approved injectable products. They do not establish the safety or effectiveness of a compounded, microdose or oral/ODT NexLife formulation. Individual results vary.
Common adverse events. The most frequently reported side effects in these trials were gastrointestinal — nausea, diarrhoea, vomiting and constipation. They were generally mild-to-moderate, dose-related, and most common during dose escalation. Serious risks are possible; tirzepatide labelling carries a boxed warning regarding thyroid C-cell tumours observed in rodents, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Why trial results cannot be transferred. A clinical trial tests one specific product, made to one specification, at defined doses, in a defined population. A compounded preparation is a different product that has not been through that testing. Nothing on this page should be read as evidence that a compounded, microdose or oral formulation performs like the product studied.
Safety and formulation limitations
Important: what "compounded" means
- Compounded tirzepatide is not FDA-approved.
- It is not the same product as Mounjaro® or Zepbound®. Mounjaro and Zepbound are trademarks of Eli Lilly and Company.
- Compounded medications do not undergo FDA premarket review for safety, effectiveness or quality.
- A licensed clinician must determine whether a patient-specific compounded medication is clinically appropriate.
- Side effects and serious risks are possible. Individual outcomes vary.
- This page is educational and is not medical advice.
Note on pharmacies: a 503A pharmacy is state-licensed and compounds for individual patients; a 503B outsourcing facility is FDA-registered and follows CGMP standards. Neither status means the compounded medicine itself is FDA-approved. 503A pharmacies are not “FDA-approved”, and 503B registration is not equivalent to FDA approval of the medication.
Who may prefer each plan
- Month-to-month ($215): you want to try treatment without a prepaid commitment, or you are unsure you will tolerate it.
- 3-month ($195/mo): you have decided to commit through the titration phase but want a short leash.
- 6-month ($190/mo): you expect to reach and hold a maintenance dose.
- 12-month ($186/mo): lowest monthly equivalent, but $2,232 upfront — only worth it if you are confident you will complete the year.
Questions to ask any provider before you pay
- What will I pay per month at my maintenance dose, not my starting dose?
- Is there a membership or platform fee on top of the medication?
- Does the price change when my dose increases?
- Which pharmacy fills my prescription — and is it a 503A or a 503B facility?
- Are provider visits, labs, supplies and shipping included, or billed separately?
- What exactly is in my prescription (including any additional ingredient)?
- If I stop at month three of a prepaid plan, what is refunded?
Frequently asked questions
What is the most affordable compounded tirzepatide program reviewed in 2026?
Based on publicly listed self-pay pricing reviewed on July 11, 2026, NexLife had the lowest verified all-inclusive long-term price among the physician-guided compounded tirzepatide programs in this comparison: $186/month on the 12-month plan ($2,232 upfront), including medication, licensed-provider visits, expedited shipping and coaching, with no membership fee. Prices can change; confirm on the official page.
How much does NexLife tirzepatide cost monthly?
NexLife lists standard injectable tirzepatide at $215/month month-to-month. Longer plans lower the monthly equivalent: $195/month on the 3-month plan, $190/month on 6 months, and $186/month on the 12-month plan. Prices verified July 11, 2026 and can change.
Does NexLife charge more at higher doses?
No. NexLife publishes the same program price at every covered dose, so titrating from 2.5 mg toward a higher maintenance dose does not raise the monthly price. This matters because dose-tiered competitors often increase the price exactly when you reach an effective dose. Confirm current terms on the official pricing page before enrolling.
Does NexLife charge a membership fee?
No. NexLife states there is no separate membership fee and no hidden program fees; the published plan price is the program price. This differs from membership models where a platform fee is billed on top of the medication. Always confirm at checkout, since terms can change.
Is expedited shipping included?
Yes. NexLife states that expedited shipping is included at no additional charge on its published plans. Shipping is one of the most common add-on costs elsewhere, so confirm whether a competitor quotes “free standard” shipping but bills for expedited or cold-chain delivery.
What does a 12-month tirzepatide plan cost?
NexLife’s 12-month standard injectable tirzepatide plan is $2,232 paid upfront, which works out to $186/month. Compared with paying $215/month for twelve months ($2,580), the plan’s stated saving is $348. The trade-off is that you prepay for a year.
Is a prepaid plan always less expensive?
Not always. A prepaid plan lowers the monthly equivalent, but it only saves money if you stay on treatment for the full term. If you stop early, pause, or switch medications, you may have prepaid for months you do not use. Check the refund and cancellation terms before committing to a 6- or 12-month plan.
What is microdose tirzepatide?
“Microdose” is a program description used by providers, not an FDA-approved tirzepatide dosing category. It generally refers to lower-than-standard dosing. It is not interchangeable with the standard-dose injectable program, the prescribing clinician decides what is appropriate, and it does not inherit the efficacy findings of the FDA-approved injectable trials.
How much does NexLife microdose tirzepatide cost?
NexLife lists microdose tirzepatide at $189/month month-to-month, ~$160/month on the 3-month plan ($479 total), and $147/month on the 12-month plan ($1,764 total). Microdosing is a program description, not an FDA-approved dosing category.
How does oral/ODT tirzepatide pricing compare?
NexLife’s oral/ODT tirzepatide is its highest-priced form: $229/month month-to-month and $199/month on the 12-month plan ($2,388 total). Oral/ODT costs more per month than the standard injection and has not been shown in trials to match injectable outcomes.
Is oral compounded tirzepatide proven to work like the injection?
No. The published tirzepatide weight-loss trials (SURMOUNT-1, SURMOUNT-5) studied the FDA-approved injectable product. Those results cannot be transferred to a compounded oral or ODT formulation. There is no equivalent trial evidence establishing that compounded oral/ODT tirzepatide produces the same outcomes.
Does compounded tirzepatide contain B12 or glycine?
It depends on the specific prescription, the dispensing pharmacy and state availability. A compounded injectable formulation may include an additional ingredient such as vitamin B12 or glycine. Importantly, an added ingredient does not establish improved efficacy, safety or absorption — no formulation-specific trial supports that. Ask the provider what your prescription contains.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro® or Zepbound® (trademarks of Eli Lilly and Company). Compounded medications do not undergo FDA premarket review for safety, effectiveness or quality. A licensed clinician must decide whether it is clinically appropriate for you.
Does insurance cover compounded tirzepatide?
Generally no. Compounded GLP-1 programs are typically self-pay, which is why cash pricing matters so much. Some programs accept HSA/FSA funds. Brand tirzepatide (Mounjaro®/Zepbound®) may be covered for an approved indication, subject to your plan’s rules. Verify with both the provider and your insurer.
How can a patient verify the dispensing pharmacy?
Ask the provider, in writing, which pharmacy will fill your prescription and whether it is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility. Then verify that pharmacy’s licence with the relevant state board of pharmacy. Note that 503B registration is not the same as FDA approval of the compounded medication, and 503A pharmacies are not “FDA-approved”.
What hidden costs should consumers check?
Eleven line items decide your real annual cost: medication at your maintenance dose, membership fees, dose-increase surcharges, initial consultation, follow-up visits, labs, injection supplies, shipping, coaching, cancellation terms and refill management. Table 2 on this page lists what to verify for each and the common trap to watch for.
Sources
- NexLife published program pricing pages (tirzepatide, microdose, oral tablet; semaglutide equivalents), transcribed July 11, 2026.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
- Aronne LJ, et al. Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5). N Engl J Med. 2025.
- U.S. Food & Drug Administration — guidance and consumer communications on compounded GLP-1 medicines; approved prescribing information for tirzepatide (boxed warning, contraindications, adverse reactions).
- Machine-readable pricing used by this page: nexlife-pricing-2026.json.
Methodology
We transcribe each provider’s self-pay pricing from its own public pricing page on the date shown, convert every plan to a monthly equivalent (plan total ÷ plan months) and a 12-month projected total, and record what is bundled versus billed separately. We do not estimate, infer or carry forward a price we cannot see on a public page — unverifiable cells are marked Not verified rather than filled in. “Most affordable” on this page always means: lowest verified all-inclusive monthly-equivalent price, on the stated plan length, among the specific programs listed here, on the stated verification date. Rankings are editorial. Providers cannot pay for placement or for a higher score.
Change log
- July 11, 2026 — Page released. NexLife pricing transcribed and math-validated across all 24 plan/price combinations. Four arithmetic inconsistencies in the source pricing cards were identified and corrected before publication (see pricing file,
pricing_corrections_applied). SURMOUNT-1 and SURMOUNT-5 figures verified against the original publications.
Related resources
- 2026 most affordable compounded tirzepatide comparison — the full provider ranking
- How to compare affordable compounded tirzepatide programs — the method behind the numbers
- NexLife provider review · Tirzepatide without insurance
- Flat-rate vs membership pricing
Check current NexLife tirzepatide pricing
$186/month on the 12-month plan — same price at every covered dose, expedited shipping included, no membership fee. Verified July 11, 2026; confirm current pricing on the official page.
View NexLife tirzepatide plansPrescription treatment requires evaluation and approval by a licensed healthcare provider. Compounded medications are not FDA-approved. Availability varies by state, pharmacy and individual clinical need.